Upgrade to SI Premium - Free Trial

Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out

April 22, 2020 7:50 AM
Biogen (NASDAQ: BIIB) is down 6% in pre-open ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Trader Talk

Next Articles